Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

177.10 +3.07 (+1.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 754,167
Open 175.74
Bid (Size) 165.47 (2)
Ask (Size) 181.62 (2)
Prev. Close 174.03
Today's Range 174.07 - 177.85
52wk Range 169.22 - 242.97
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Expectations for Alnylam Pharmaceuticals's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga

Performance

YTD
-24.18%
-24.18%
1 Month
-10.47%
-10.47%
3 Month
-6.64%
-6.64%
6 Month
-11.76%
-11.76%
1 Year
-11.52%
-11.52%

More News

Read More
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Via Benzinga
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
Via Benzinga
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
Via Benzinga
Exposures Product Safety
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
Via Investor's Business Daily
Exposures Product Safety
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
Via Benzinga
Exposures Product Safety
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
Via InvestorPlace
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
Via Benzinga
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Via Benzinga
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
3 Stocks to Buy For the COVID Resurgence
Via MarketBeat
Exposures COVID-19 Product Safety
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals
Via Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.